Altamira Therapeutics Ltd. Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used
Altamira Therapeutics Ltd. (CYTOF) reported Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used of $40.93 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ExpenseRelatingToShorttermLeasesForWhichRecognitionExemptionHasBeenUsed · last filed 2025-04-30
USD
| Period end | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 12 month |
|---|---|
| 2024-12-31 | $40.93K 20-F · filed 2025-04-30 |
| 2023-12-31 | $7.35K 20-F · filed 2025-04-30 |
| 2021-12-31 | $52.28K 20-F · filed 2022-04-12 |
| 2020-12-31 | $61.51K 20-F · filed 2022-04-12 |
CHF
| Period end | Expense Relating To Shortterm Leases For Which Recognition Exemption Has Been Used 12 month |
|---|---|
| 2023-12-31 | 6.60K CHF 20-F/A · filed 2024-04-22 |
| 2022-12-31 | 6.00K CHF 20-F/A · filed 2024-04-22 |
| 2021-12-31 | 52.28K CHF 20-F · filed 2023-05-16 |